更昔洛韦治疗对免疫功能低下患者白细胞中巨细胞病毒DNA数量的早期影响。
Early effects of ganciclovir therapy on the quantity of cytomegalovirus DNA in leukocytes of immunocompromised patients.
作者信息
Boivin G, Quirk M R, Kringstad B A, Germain M, Jordan M C
机构信息
Department of Microbiology, Université Laval, Quebec City, Quebec, Canada.
出版信息
Antimicrob Agents Chemother. 1997 Apr;41(4):860-2. doi: 10.1128/AAC.41.4.860.
Abstract
The cytomegalovirus (CMV) DNA load in leukocytes was measured in 26 immunocompromised patients with CMV disease before and after 10 days of intravenous ganciclovir therapy. Before therapy, the circulating DNA burden of bone marrow transplant recipients was significantly lower than that of other transplant or AIDS patients. Ganciclovir induction therapy significantly decreased the viral DNA load in the leukocyte populations of most patients.
摘要
在26例患有巨细胞病毒（CMV）疾病的免疫功能低下患者中，在静脉注射更昔洛韦治疗10天前后测量了白细胞中的CMV DNA载量。治疗前，骨髓移植受者的循环DNA负荷显著低于其他移植患者或艾滋病患者。更昔洛韦诱导治疗显著降低了大多数患者白细胞群体中的病毒DNA载量。
相似文献
1
Early effects of ganciclovir therapy on the quantity of cytomegalovirus DNA in leukocytes of immunocompromised patients.
Antimicrob Agents Chemother. 1997 Apr;41(4):860-2. doi: 10.1128/AAC.41.4.860.
2
Use of a semi-quantitative PCR for cytomegalovirus DNA as a basis for pre-emptive antiviral therapy in allogeneic bone marrow transplant patients.
Bone Marrow Transplant. 1996 Apr;17(4):583-7.
3
A randomized, controlled trial comparing ganciclovir to ganciclovir plus foscarnet (each at half dose) for preemptive therapy of cytomegalovirus infection in transplant recipients.
J Infect Dis. 2004 Apr 15;189(8):1355-61. doi: 10.1086/383040. Epub 2004 Apr 1.
4
Cytomegalovirus (CMV) DNA load predicts relapsing CMV infection after solid organ transplantation.
J Infect Dis. 2000 Feb;181(2):717-20. doi: 10.1086/315242.
5
[Impact of initial cytomegalovirus viral load on efficacy of preemptive therapy with ganciclovir in allogeneic stem cell transplant recipients].
Enferm Infecc Microbiol Clin. 2010 Jan;28(1):6-12. doi: 10.1016/j.eimc.2009.01.010. Epub 2009 May 1.
6
Ganciclovir. An update of its use in the prevention of cytomegalovirus infection and disease in transplant recipients.
Drugs. 1998 Jul;56(1):115-46. doi: 10.2165/00003495-199856010-00012.
7
Human cytomegalovirus DNA kinetics using a novel HCMV DNA quantitative assay in white blood cells of immunocompromised patients under Ganciclovir therapy.
J Virol Methods. 1997 Apr;65(1):131-8. doi: 10.1016/s0166-0934(97)02180-0.
8
Quantitative polymerase chain reaction to predict occurrence of symptomatic cytomegalovirus infection and assess response to ganciclovir therapy in renal transplant recipients.
J Infect Dis. 1998 Sep;178(3):626-35. doi: 10.1086/515383.
9
Emergence of ganciclovir-resistant cytomegalovirus in lung transplant recipients.
J Heart Lung Transplant. 2002 Dec;21(12):1274-82. doi: 10.1016/s1053-2498(02)00463-1.
10
Cytomegalovirus resistance in solid organ transplant recipients treated with intravenous ganciclovir or oral valganciclovir.
Antivir Ther. 2009;14(5):697-704.
引用本文的文献
1
Murine Cytomegalovirus Spread Depends on the Infected Myeloid Cell Type.
J Virol. 2019 Jul 17;93(15). doi: 10.1128/JVI.00540-19. Print 2019 Aug 1.
2
A prospective study comparing quantitative Cytomegalovirus (CMV) polymerase chain reaction in plasma and pp65 antigenemia assay in monitoring patients after allogeneic stem cell transplantation.
BMC Infect Dis. 2006 Nov 21;6:167. doi: 10.1186/1471-2334-6-167.
3
Comparative quantitation of cytomegalovirus (CMV) DNA in solid organ transplant recipients with CMV infection by using two high-throughput automated systems.
J Clin Microbiol. 2001 Dec;39(12):4472-6. doi: 10.1128/JCM.39.12.4472-4476.2001.
4
Quantitative analysis of cytomegalovirus (CMV) viremia using the pp65 antigenemia assay and the COBAS AMPLICOR CMV MONITOR PCR test after blood and marrow allogeneic transplantation.
J Clin Microbiol. 2000 Dec;38(12):4356-60. doi: 10.1128/JCM.38.12.4356-4360.2000.
5
Clinical relevance of direct quantification of pp65 antigenemia using flow cytometry in solid organ and stem cell transplant recipients.
J Clin Microbiol. 2000 Sep;38(9):3143-9. doi: 10.1128/JCM.38.9.3143-3149.2000.
6
New strategies for prevention and therapy of cytomegalovirus infection and disease in solid-organ transplant recipients.
Clin Microbiol Rev. 2000 Jan;13(1):83-121, table of contents. doi: 10.1128/CMR.13.1.83.
7
Evaluation of the AMPLICOR cytomegalovirus test with specimens from human immunodeficiency virus-infected subjects.
J Clin Microbiol. 1998 Sep;36(9):2509-13. doi: 10.1128/JCM.36.9.2509-2513.1998.
8
Quantitation of cytomegalovirus: methodologic aspects and clinical applications.
Clin Microbiol Rev. 1998 Jul;11(3):533-54. doi: 10.1128/CMR.11.3.533.
9
Utility of major leukocyte subpopulations for monitoring secondary cytomegalovirus infections in renal-allograft recipients by PCR.
J Clin Microbiol. 1998 Apr;36(4):1008-14. doi: 10.1128/JCM.36.4.1008-1014.1998.
本文引用的文献
1
Effect of foscarnet on quantities of cytomegalovirus and human immunodeficiency virus in blood of persons with AIDS.
Antimicrob Agents Chemother. 1996 Dec;40(12):2721-6. doi: 10.1128/AAC.40.12.2721.
2
Detection of ganciclovir resistance mutations quantitation of cytomegalovirus (CMV) DNA in leukocytes of patients with fatal disseminated CMV disease.
J Infect Dis. 1996 Mar;173(3):523-8. doi: 10.1093/infdis/173.3.523.
3
Cytomegalovirus antigenemia: clinical correlations in transplant recipients and in persons with AIDS.
J Clin Microbiol. 1993 Oct;31(10):2824-7. doi: 10.1128/jcm.31.10.2824-2827.1993.
4
Quantification of human cytomegalovirus DNA in peripheral blood polymorphonuclear leukocytes of immunocompromised patients by the polymerase chain reaction.
J Virol Methods. 1993 Sep;44(1):45-55. doi: 10.1016/0166-0934(93)90006-d.
5
Effect of foscarnet induction treatment on quantitation of human cytomegalovirus (HCMV) DNA in peripheral blood polymorphonuclear leukocytes and aqueous humor of AIDS patients with HCMV retinitis. The Italian Foscarnet Study Group.
Antimicrob Agents Chemother. 1994 Jan;38(1):38-44. doi: 10.1128/AAC.38.1.38.
6
High levels of HIV-1 in plasma during all stages of infection determined by competitive PCR.
Science. 1993 Mar 19;259(5102):1749-54. doi: 10.1126/science.8096089.
7
Comparison of PCR and pp65 antigenemia assay with quantitative shell vial culture for detection of cytomegalovirus in blood leukocytes from solid-organ transplant recipients.
J Clin Microbiol. 1994 Apr;32(4):997-1003. doi: 10.1128/jcm.32.4.997-1003.1994.
8
Comparative quantitation of human cytomegalovirus DNA in blood leukocytes and plasma of transplant and AIDS patients.
J Clin Microbiol. 1994 Nov;32(11):2709-17. doi: 10.1128/jcm.32.11.2709-2717.1994.
9
Quantitation of human cytomegalovirus DNA from peripheral blood cells of human immunodeficiency virus-infected patients could predict cytomegalovirus retinitis.
J Infect Dis. 1995 Jan;171(1):177-82. doi: 10.1093/infdis/171.1.177.
10
Quantitation of human cytomegalovirus glycoprotein H gene in cells using competitive PCR and a rapid fluorescence-based detection system.
J Virol Methods. 1995 Feb;51(2-3):329-42. doi: 10.1016/0166-0934(94)00128-4.
Zotero 插件